MeiraGTx Holdings (MGTX) Consolidated Net Income (2017 - 2025)
MeiraGTx Holdings (MGTX) posted Consolidated Net Income of $15.9 million for Q4 2025, up 132.46% on a QoQ basis from -$49.0 million in Q3 2025, and up 149.36% year-over-year from $6.4 million in Q4 2024.
MeiraGTx Holdings (MGTX) Consolidated Net Income (2017 - 2025) Analysis & Trends
MeiraGTx Holdings' Consolidated Net Income history runs 9 years deep, the most recent figure standing at $15.9 million for Q4 2025.
- Quarterly Consolidated Net Income rose 149.36% year-over-year to $15.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$122.1 million (up 29.69% YoY) and the FY2025 annual result came in at -$287.2 million, up 7.19% from the prior year.
- Consolidated Net Income was $15.9 million for Q4 2025 at MeiraGTx Holdings, up from -$49.0 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $15.9 million in Q4 2025 and bottomed at -$51.0 million in Q2 2024.
- A 5-year average of -$29.3 million and a median of -$31.8 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 927.97% — and 2025, when it soared 149.36%.
- MeiraGTx Holdings' Consolidated Net Income stood at -$4.3 million in 2021, then plunged by 927.97% to -$44.0 million in 2022, then soared by 114.9% to $6.5 million in 2023, then slumped by 591.63% to -$32.2 million in 2024, then surged by 149.36% to $15.9 million in 2025.
- Business Quant data shows MGTX's Consolidated Net Income at $15.9 million in Q4 2025, -$49.0 million in Q3 2025, and -$41.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 205.99 Mn |
| 10 | MeiraGTx Holdings | 997.33 Mn | 931.40 Mn | - | 15.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.89 Mn |
| Sep 30, 2025 | -48.96 Mn |
| Jun 30, 2025 | -41.42 Mn |
| Mar 31, 2025 | -47.63 Mn |
| Dec 31, 2024 | -32.20 Mn |
| Sep 30, 2024 | -41.50 Mn |
| Jun 30, 2024 | -51.05 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Dec 31, 2023 | 6.55 Mn |
| Sep 30, 2023 | -35.62 Mn |
| Jun 30, 2023 | -31.49 Mn |
| Mar 31, 2023 | -34.28 Mn |
| Dec 31, 2022 | -43.96 Mn |
| Sep 30, 2022 | -24.41 Mn |
| Jun 30, 2022 | -25.08 Mn |
| Mar 31, 2022 | -30.09 Mn |
| Dec 31, 2021 | -4.28 Mn |
| Sep 30, 2021 | -23.75 Mn |
| Jun 30, 2021 | -21.67 Mn |
| Mar 31, 2021 | -23.13 Mn |